Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of upadacitinib for induction and maintenance treatment in moderate to severe ulcerative colitis
MOH_2017-03-21_000108Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in autoimmune colitis (6 arms), sponsored by AbbVie Inc. Started Jan 2017; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-03-21_000108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-21_000108.